MAY 23, 2020 8:03 AM PDT

A New Biomarker to Identify a Triple Negative Breast Cancer Prognosis

WRITTEN BY: Jasper Cantrell

Breast cancer, one of the most common cancers in the world, are commonly separated into one of several sub-types. These can be identified by the overexpression or progesterone, and/or estrogen, or HER2. Triple negative breast cancer (TNBC) is when none of these are over-expressed, and this type of breast cancer is often quite aggressive and hard to treat. A group from France was investigating a protein called EPS15 homology domain containing protein 2 (EHD2), and decided to investigate a new possible link between EHD2 and TNBC.

EHD2 is a protein involved in the stabilization of something called caveolae, an area of the plasma membrane with high tension. Recent work connects low levels of EHD2 to a poor prognosis in esophageal squamous cell carcinoma patients, as well as a few other cancer types. The team decided to examine this association in breast cancer. To do this, they gathered a 526 breast cancer patient pool running back 30 years and began to measure EHD2 levels.

Starting off, they followed EHD2 mRNA levels. Low levels of EHD2 was found to be strongly associated with several poor prognostic phenotypes such as cellular proliferation and the TNBC sub-type. Measuring actual EHD2 protein levels agreed with this finding. A follow up in vitro assay using 22 breast cancer cell lines confirmed that there was a strong association with the TNBC sub-type and low EHD2 levels. Choosing three TNBC cell lines to represent high, medium, and low EHD2 levels, they identified a strong positive correlation between EHD2 levels and many phenotypes of aggressive cancers such as invasiveness and cellular proliferation. They also found that the pro-cancer cytokine IL-8 had a negative correlation with EHD2. This meant that when EHD2 levels were low, IL-8s were high and a pro-cancer phenotype could be observed.

The group then moved back to testing the initial patient pool for any EHD2 connections. As if to contradict the in vitro finding, low levels of EHD2 in TNBC patients was associated with a better metastatic-free survival (MFS) rate. Low EHD2 levels in TNBC patients also correlated with a good response to chemotherapy. This could be explained by a past observation of chemotherapy being effective against cancers with a strong cellular proliferation phenotype, however this work could not delve to deep into this aspect.

As a prognostic factor for TNBC patients, EHD2 seems to be able to indicate a good response for chemotherapies and MFS. The group notes the link between EHD2 and IL-8 is likely the reason for the in vitro pro-cancer phenotype seen in this study, as well as a possible mechanism by which chemotherapy might work better on low EHD2 level TNBCs. Chemotherapy has been shown to be effective against cancers with a high cellular proliferation phenotype. They conclude “Altogether, our study not only reveals that EHD2 acts as a tumor suppressor, it is also a new independent prognostic factor of metastasis-free survival and a new biomarker of chemotherapy response in TNBC patients.”
 

Sources: Nature, OncLiveTV

About the Author
Bachelor's (BA/BS/Other)
Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
NOV 14, 2022
Cancer
Breast Cancer Vaccine Shows Promise as it Enters Phase 2 Trial
Breast Cancer Vaccine Shows Promise as it Enters Phase 2 Trial
About 20% of breast cancers exhibit elevated levels of a protein known as HER2.  You may have heard the classifier ...
NOV 28, 2022
Clinical & Molecular DX
Study Indicates that Breast Cancer Recurrence Could be Predicted Using a MicroRNA Biomarker
Study Indicates that Breast Cancer Recurrence Could be Predicted Using a MicroRNA Biomarker
MicroRNAs are small (between just 21 and 23 nucleotides), non-coding RNA molecules. They are involved in the post-transc ...
DEC 14, 2022
Genetics & Genomics
Labroots' Top 10 Scientific Discoveries of 2022
Labroots' Top 10 Scientific Discoveries of 2022
2022 was a big year for science, so let’s take a look at some of the most interesting -and important- scientific d ...
DEC 22, 2022
Technology
Handheld Device for Detecting Oral Cancer
Handheld Device for Detecting Oral Cancer
According the that National Cancer Institute, cancers of the oral cavity and pharynx are expected to have accounted for ...
JAN 19, 2023
Cell & Molecular Biology
Revealing the Molecules Underlying Metastasis
Revealing the Molecules Underlying Metastasis
Cancer is at its deadliest when it metastasizes - when cancer cells break away from a tumor and migrate to other tissues ...
JAN 30, 2023
Cancer
Kiwi Juice Provides Therapeutic Benefit in Lung Cancer Model
Kiwi Juice Provides Therapeutic Benefit in Lung Cancer Model
Actinidia arguta, commonly known as the hardy kiwi or kiwi berry, looks like a smaller, hairless version of the Actinidi ...
Loading Comments...